Madrigal Pharmaceuticals, Inc. cash flow to debt ratio of -53.49% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Madrigal Pharmaceuticals, Inc.'s free cash flow has increased -58.42% from $-457.03M last year to $-190.02M, signaling increasing performance

Madrigal Pharmaceuticals, Inc.'s debt to equity ratio is 0.66, which means that the company's assets are unhealthy financed, signaling financial risk.

Madrigal Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.16 last year to 0.66 today, signaling weakened financials

Madrigal Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Madrigal Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Madrigal Pharmaceuticals, Inc.'s profit margin has increased (-90.21%) in the last year from -258.64% to -25.32%, signaling increasing performance

Madrigal Pharmaceuticals, Inc.'s short-term assets of $1.25B exceed its short-term liabilities of $310.29M

Madrigal Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Madrigal Pharmaceuticals, Inc.'s return on equity of -56.65%, is lower than 15.00%, indicating bad performance

Madrigal Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Madrigal Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Madrigal Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Madrigal Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Madrigal Pharmaceuticals, Inc.'s yearly earnings has increased -38.12% since last year from $-465.89M to $-288.28M, signaling increasing performance

Madrigal Pharmaceuticals, Inc.'s yearly revenue has increased 432.05% since last year from $180.13M to $958.40M, signaling increasing performance

ROIC -37.02% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Madrigal Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Madrigal Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Madrigal Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Madrigal Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Madrigal Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Madrigal Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Madrigal Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Madrigal Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Madrigal Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Madrigal Pharmaceuticals, Inc. has a price-to-book ratio of 28.68x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Madrigal Pharmaceuticals, Inc. has a price-to-sales ratio of 11.70x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue